{"id":"post-radiotherapy-commencement-of-anastrozole","safety":{"commonSideEffects":[{"rate":"36","effect":"Hot flashes"},{"rate":"35","effect":"Arthralgia/joint pain"},{"rate":"19","effect":"Fatigue"},{"rate":"12","effect":"Vaginal dryness"},{"rate":null,"effect":"Osteoporosis/bone loss"},{"rate":null,"effect":"Elevated cholesterol"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anastrozole selectively inhibits the aromatase enzyme, which catalyzes the final step of estrogen synthesis in postmenopausal women. By reducing circulating estrogen levels, it suppresses the growth of estrogen-dependent breast cancer cells. In this trial context, it is being evaluated as adjuvant therapy initiated after radiotherapy completion in early-stage breast cancer.","oneSentence":"Anastrozole is an aromatase inhibitor that blocks the conversion of androgens to estrogen, reducing estrogen levels in postmenopausal women with hormone receptor-positive breast cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:42.983Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Early-stage hormone receptor-positive breast cancer, adjuvant therapy post-radiotherapy in postmenopausal women"}]},"trialDetails":[{"nctId":"NCT00887380","phase":"PHASE3","title":"STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing)","status":"UNKNOWN","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2009-09-16","conditions":"Breast Cancer","enrollment":2023},{"nctId":"NCT03948568","phase":"PHASE4","title":"Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2019-09-17","conditions":"Early-stage Breast Cancer","enrollment":262},{"nctId":"NCT01402193","phase":"PHASE3","title":"Study of Arimidex and Radiotherapy Sequencing","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2011-07","conditions":"Breast Cancer","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Arimidex"],"phase":"phase_3","status":"active","brandName":"Post radiotherapy commencement of anastrozole","genericName":"Post radiotherapy commencement of anastrozole","companyName":"Trans Tasman Radiation Oncology Group","companyId":"trans-tasman-radiation-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anastrozole is an aromatase inhibitor that blocks the conversion of androgens to estrogen, reducing estrogen levels in postmenopausal women with hormone receptor-positive breast cancer. Used for Early-stage hormone receptor-positive breast cancer, adjuvant therapy post-radiotherapy in postmenopausal women.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}